Arvinas to Present at Upcoming Conferences

NEW HAVEN, Conn., Nov. 01, 2022 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in two upcoming confe…

Arvinas Gives Back to Local Greater New Haven Community

NEW HAVEN, Conn., Sept. 30, 2022 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that nearly 200 employees participated in the…

Arvinas Gives Back to Local Greater New Haven Community

NEW HAVEN, Conn., Sept. 30, 2022 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that nearly 200 employees participated in the…